Abstract
Mineral excretion following single doses of furosemide were compared with bumetanide in a random cross-over trial in 17 premature infants. The mean birth-weight and gestational age were 889±85 g and 27±2 weeks. Following furosemide therapy, significantly higher chloride losses and urine volumes were noted in the first 8-h period compared with the second or third 8-h periods. Following bumetanide therapy, sodium, calcium, and chloride losses and urine volumes were significantly higher in the first 8 h compared with the second or third 8-h periods. Hourly sodium and chloride losses were significantly lower following bumetanide than furosemide during the first two 8-h periods. During the final 8-h period sodium, potassium, chloride, and calcium losses were significantly lower following bumetanide than following furosemide. Sodium loss per urine volume was lower with bumetanide than furosemide but calcium loss tended to be higher. Hence, bumetanide does not appear to be a calciumsparing diuretic following single-dose therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kao LC, Warbuton DW, Sargent CW, Platzker ACG, Keens TG (1983) Furosemide acutely decreases airway resistance in chronic bronchopulmonary dysplasia. J Pediatr 103: 624–629
McCann EM, Lewis K, Deming DD, Donovan MJ, Brady JP (1985) Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediatr 106: 957–962
Englehardt B, Elliott S, Hazinski TA (1986) Short-and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia. J Pediatr 109: 1034–1039
Albersheim SG, Solimano AJ, Sharma AK, Smyth JA, Rothschild A, Wood BJ, Sheps SB (1989) Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr 115: 615–620
Green TP, Thompson TR, Johnson DE, Lock JE (1983) Diuresis and pulmonary function in premature infants with respiratory distress syndrome. J Pediatr 103: 618–623
Yeh TF, Shibli A, Leu ST, Raval D, Pildes RS (1984) Early furosemide therapy in premature infants (<-2000 g) with respiratory distress syndrome: a randomized controlled trial. J Pediatr 105: 603–609
Wiswell TE, Rawlings JS, Smith FR, Goo ED (1985) Effect of furosemide on the clinical course of transient tachypnea of the newborn. Pediatrics 75: 908–910
Hufnagle KG, Khan SN, Penn D, Caciarelli A, Williams P (1982) Renal calcification: a complication of long term furosemide therapy in preterm neonates. Pediatrics 70: 360–363
Ezzedeen F, Adelman RD, Ahlfors CE (1988) Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr 113: 532–539
Downing GJ, Egelhoff JC, Daily DK, Thomas MK, Alon U (1992) Kidney function in very low birthweight infants with furosemiderelated renal calcification at ages 1 and 2 years. J Pediatr 120: 599–604
Venkataraman PS, Han BK, Tsang RC, Daugherty CC (1983) Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy. Am J Dis Child 137: 1157–1161
Vileisis RA (1990) Furosemide effect on mineral status of parenterally nourished premature neonates with chronic lung disease. Pediatrics 85: 316–322
Perlman JM, Moore V, Seigal MJ, Dawson J (1986) Is chloride depletion an important contributing cause of death in infants with bronchopulmonary dysplasia? Pediatrics 77: 212–216
Davies DL, Lant AF, Millard NR, Smith AJ, Ward JW, Wilson GM (1974) Renal action, therapeutic use and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther 15: 141–155
Ramsay LE, McInnes GT, Hettiarachchi J, Shelton J, Scott P (1978) Bumetanide and furosemide: a comparison of dose-response curves in healthy men. Br J Clin Pharmacol 5: 243–247
Halstenson CE, Matzke GR (1983) Bumetanide: a new loop diuretic. Drug Intell Clin Pharm 17: 786–797
Ward OC, Lam LKT (1977) Bumetanide in heart failure in infancy. Arch Dis Child 52: 877–882
Witte MK, Rudloff AC, Yamashita TS, Blumer JL (1986) Dose ranging pharmacokinetic and pharmacodynamic evaluating of bumetanide in infants with volume overload (abstract). Pediatr Res 20: 210A
Gale R, Armon Y, Aranda JV (1988) Pharmacodynamic profile of bumetanide in newborn infants (abstract). Pediatr Res 23: 257A
Shankaran S, Ilagan N, Liang K, Bhawsar V, Kauffman R (1989) Bumetanide pharmacokinetics in preterm neonates (abstract). Pediatr Res 25: 72A
Wells TG, Fasules JW, Taylor BJ, Kearns GL (1992) Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. J Pediatr 121: 974–980
Atkinson SA, Shah JK, McGee, Steele BT (1988) Mineral excretion in premature infants receiving various diuretic therapies. J Pediatr 113: 540–545
Chemtob S, Doray JL, Laudingnon N, Papageorgiou A, Varma DR, Aranda JV (1989) Alternating sequential dosing with furosemide and ethacrynic acid in drug tolerance in the newborn. Am J Dis Child 143: 850–854
Segar JL, Robillard JE, Johnson KJ, Bell EF, Chemtob S (1992) Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. J Pediatr 120: 966–973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shankaran, S., Liang, Kc., Ilagan, N. et al. Mineral excretion following furosemide compared with bumetanide therapy in premature infants. Pediatr Nephrol 9, 159–162 (1995). https://doi.org/10.1007/BF00860731
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00860731